<p><em>Lugano, Switzerland, 17 October 2023</em> – More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumour cells, with less need for chemotherapy, following results of multiple landmark clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023.</p>
/PRNewswire/ Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology portfolio and pipeline at the European Society for.